• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Nonsquamous NSCLC Harboring EGFR Mutations.

作者信息

Zhao Binghao, Xing Hao, Ma Wenbin

机构信息

Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.

Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.

出版信息

J Thorac Oncol. 2022 Sep;17(9):e76-e77. doi: 10.1016/j.jtho.2022.06.005.

DOI:10.1016/j.jtho.2022.06.005
PMID:36031292
Abstract
摘要

相似文献

1
Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Nonsquamous NSCLC Harboring EGFR Mutations.奥希替尼联合贝伐单抗对比奥希替尼用于治疗未经治疗的携带表皮生长因子受体（EGFR）突变的非鳞状非小细胞肺癌
J Thorac Oncol. 2022 Sep;17(9):e76-e77. doi: 10.1016/j.jtho.2022.06.005.
2
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study.奥希替尼联合贝伐珠单抗对比奥希替尼一线治疗携带 EGFR 突变的非鳞状非小细胞肺癌的随机 II 期研究：WJOG9717L 研究。
J Thorac Oncol. 2022 Sep;17(9):1098-1108. doi: 10.1016/j.jtho.2022.05.006. Epub 2022 May 27.
3
Usage of Radiotherapy With Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations.奥希替尼联合贝伐单抗与奥希替尼用于未经治疗的携带EGFR突变的非鳞状非小细胞肺癌患者的放射治疗应用
J Thorac Oncol. 2023 Jan;18(1):e3-e4. doi: 10.1016/j.jtho.2022.10.010.
4
Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC.简短报告：ⅢA期表皮生长因子受体（EGFR）突变型非小细胞肺癌（NSCLC）新辅助奥希替尼分子分析策略的评估
Clin Lung Cancer. 2024 Jan;25(1):e58-e61. doi: 10.1016/j.cllc.2023.08.012. Epub 2023 Aug 30.
5
Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?奥希替尼用于非小细胞肺癌及罕见表皮生长因子受体（EGFR）突变患者——追逐独角兽？
JAMA Oncol. 2024 Jan 1;10(1):52-53. doi: 10.1001/jamaoncol.2023.5004.
6
Patients with uncommon EGFR mutations also benefit from first-line osimertinib.具有罕见表皮生长因子受体（EGFR）突变的患者也能从一线使用奥希替尼中获益。
Nat Rev Clin Oncol. 2024 Feb;21(2):84. doi: 10.1038/s41571-023-00847-x.
7
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.一项比较奥希替尼联合贝伐珠单抗与奥希替尼单药二线治疗表皮生长因子受体（EGFR）阳性且获得性 T790M 突变的晚期非小细胞肺癌（NSCLC）的随机 II 期研究：欧洲胸部肿瘤平台（ETOP）10-16 BOOSTER 试验。
Ann Oncol. 2022 Feb;33(2):181-192. doi: 10.1016/j.annonc.2021.11.010. Epub 2021 Nov 26.
8
Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.奥希替尼：完全切除的、早期、EGFR 突变阳性 NSCLC 中的研究。
Target Oncol. 2022 May;17(3):369-376. doi: 10.1007/s11523-022-00883-0. Epub 2022 Jun 17.
9
A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.一位携带有罕见表皮生长因子受体（EGFR）L858R/V843I 突变复合物的非小细胞肺癌（NSCLC）患者从奥希替尼治疗中获益：一例报告。
Ann Palliat Med. 2022 Mar;11(3):1121-1125. doi: 10.21037/apm-21-2653.
10
Combination of Bevacizumab and Osimertinib in Patients with EGFR T790M-Mutated Non-small Cell Lung Cancer.贝伐单抗与奥希替尼联合用于EGFR T790M突变的非小细胞肺癌患者
Clin Drug Investig. 2022 May;42(5):459-464. doi: 10.1007/s40261-022-01145-7. Epub 2022 May 5.